Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Gilteritinib in R/R AML

Naval Daver • 1 Sep 2020
SOHO 2020
Acute Myeloid Leukemia Leukemia Azacitidine Cytarabine Gilteritinib Venetoclax
ADMIRAL

Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the use of gilteritinib, a tyrosine kinase inhibitor, in relapsed/refractory (R/R) FLT3m+ acute myeloid leukemia (AML) patients. Dr Daver discusses the results of the ADMIRAL study (NCT02421939), evaluating gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML, as well as an ongoing study evaluating gilteritinib in combination with azacitidine. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Naval Daver

New treatments in AML: FLT3 inhibitors & novel combinations
Gail Roboz et al. • 4 Sep 2023
3:53
Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AML
Naval Daver • 12 Dec 2022
1:13
The importance of CD47 as a target in MDS and AML
Naval Daver • 12 Dec 2022
3:50
Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with AML
Naval Daver • 12 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals